Last reviewed · How we verify
The high-dose group of ZL-82 tablets — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
The high-dose group of ZL-82 tablets (The high-dose group of ZL-82 tablets) — Chengdu Zenitar Biomedical Technology Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| The high-dose group of ZL-82 tablets TARGET | The high-dose group of ZL-82 tablets | Chengdu Zenitar Biomedical Technology Co., Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- The high-dose group of ZL-82 tablets CI watch — RSS
- The high-dose group of ZL-82 tablets CI watch — Atom
- The high-dose group of ZL-82 tablets CI watch — JSON
- The high-dose group of ZL-82 tablets alone — RSS
Cite this brief
Drug Landscape (2026). The high-dose group of ZL-82 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/the-high-dose-group-of-zl-82-tablets. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab